<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470037</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH105-REC1-023</org_study_id>
    <nct_id>NCT04470037</nct_id>
  </id_info>
  <brief_title>Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder</brief_title>
  <official_title>Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading&#xD;
      neurodegenerative disorders. Considering the fact that aged population is rapidly growing, it&#xD;
      has become a critical issue to find more effective medications for these two disorders. The&#xD;
      aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD&#xD;
      with dementia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading&#xD;
      neurodegenerative disorders. Despite some therapeutic benefits from the medications targeting&#xD;
      at cholinergic and dopaminergic pathways in AD and PD respectively, it remains far away from&#xD;
      a satisfied treatment goal. DAAOI-P is a D-amino acid oxidase (DAAO) inhibitor and an agent&#xD;
      specific to facilitate NMDA receptor subunit 1 (NR1). The investigators have demonstrated&#xD;
      that NMDA-enhancement can help PD-D patients. The aim of this project is to examine the&#xD;
      effectiveness and safety of DAAOI-P treatment for PD with dementia. In addition to evaluating&#xD;
      clinical treatment response, multidisciplinary examinations, including&#xD;
      electroencephalography, transcranial magnetic stimulation, magnetic resonance imaging (MRI),&#xD;
      and psychophysical methods to analyze the changes in perceptual sensitivity to faces, emotion&#xD;
      expressions, and biological motion recognition will be arranged to elucidate the underlying&#xD;
      mechanism of NMDA modulation in neurodegenerative disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of gait and neuropsychiatric symptoms</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in Unified Parkinson's Disease Rating Scale (UPDRS)&#xD;
UPDRS: Unified Parkinson's Disease Rating Scale Minimum value: 0 Maximum value: 199 The higher score means a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gait function</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>The Cyclogram of Gait&#xD;
Minimum value: 0 Maximum value: 100 The higher score means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fall assessment</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>The fall assessment test of China Medical University Hospital&#xD;
Minimum value: 0 Maximum value: 10 The higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)&#xD;
ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale Minimum value: 0 Maximum value: 70 The higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric symptoms</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in Neuropsychiatry Inventory (NPI)&#xD;
NPI: Neuropsychiatry Inventory Minimum value: 0 Maximum value: 144 The higher score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of Parkinson's disease</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in The 39-item Parkinson's Disease Questionnaire (PDQ-39)&#xD;
PDQ-39: The 39-item Parkinson's Disease Questionnaire Minimum value: 0 Maximum value: 156 The higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Pathology of dementia</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)&#xD;
Behave-AD: Behavioral Pathology in Alzheimer's Disease Rating Scale Minimum value: 0 Maximum value: 75 The higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of dementia</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in Clinical Dementia Rating (CDR)&#xD;
CDR: Clinical Dementia Rating Minimum value: 0 Maximum value: 5 The higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging examinations</measure>
    <time_frame>week 0, 24</time_frame>
    <description>Neuroimaging examinations contains: (1) Structural MRI, (2) Resting-state fMRI, and (3) Working memory fMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Face perception</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Changes in perceptual discriminability (d-prime index)&#xD;
Minimum value: 0 (chance level); Maximum value: 3.0 (nearly perfect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion recognition and imitation</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Changes in emotion recognition accuracy and imitation probability&#xD;
Minimum value: 0%; Maximum value: 100% (Higher score indicate a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcranial magnetic stimulation</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Change in Transcranial Magnetic Stimulation (TMS) assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Changes in Mismatch negativity (MMN)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson's Disease With Dementia</condition>
  <arm_group>
    <arm_group_label>DAAOI-P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAAOI-P 250-1500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starch pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAAOI-P</intervention_name>
    <description>DAAOI-P 250-1500mg</description>
    <arm_group_label>DAAOI-P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>starch pill</description>
    <arm_group_label>Starch pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PD-D will be diagnosed according to the criteria proposed by Movement Disorder Society&#xD;
             task force statement. (Emre et al. 2007) . The following wordings are modified from&#xD;
             the task force statement. I. Core features&#xD;
&#xD;
               1. Diagnosis of PD according to Queen Square Brain Bank criteria&#xD;
&#xD;
               2. A dementia syndrome with insidious onset and slow progression, developing within&#xD;
                  the context of established PD and diagnosed by history, clinical, and mental&#xD;
                  examination, defined as:&#xD;
&#xD;
                    -  Impairment in more than one cognitive domain&#xD;
&#xD;
                    -  Representing a decline from premorbid level&#xD;
&#xD;
                    -  Deficits severe enough to impair daily life, independent of the impairment&#xD;
                       ascribable to motor or autonomic symptoms&#xD;
&#xD;
                    -  MMSE score between 10-26.&#xD;
&#xD;
        II. Associated clinical features&#xD;
&#xD;
          1. Cognitive features: Impaired attention, executive functions, visuo-spatial functions&#xD;
             or memory. Core functions of language are largely preserved.&#xD;
&#xD;
          2. Behavioral features:&#xD;
&#xD;
               -  Apathy&#xD;
&#xD;
               -  Changes in personality and mood&#xD;
&#xD;
               -  Hallucinationâ€¢ Delusions&#xD;
&#xD;
               -  Excessive daytime sleepiness&#xD;
&#xD;
        III. Features which do not exclude PD-D, but make the diagnosis uncertain&#xD;
&#xD;
          -  Co-existence of any other abnormality which may by itself cause cognitive impairment,&#xD;
             but judged not to be the cause of dementia.&#xD;
&#xD;
          -  Time interval between the development of motor and cognitive symptoms is uncertain&#xD;
&#xD;
        IV. Features suggesting other conditions or diseases as cause of mental impairment, which,&#xD;
        when present make it impossible to reliably diagnose PD-D&#xD;
&#xD;
          -  Cognitive and behavioral symptoms appearing solely in the context of other conditions&#xD;
             such as:&#xD;
&#xD;
               1. Acute confusion due to systemic illnesses or drug intoxication.&#xD;
&#xD;
               2. Major depression&#xD;
&#xD;
          -  Features compatible with &quot;Probable Vascular dementia&quot; criteria according to&#xD;
             NINDS-AIREN Criteria for the diagnosis of probable and possible PD-D [Probable PD-D]&#xD;
             Both core features must be present. In associated clinical features, typical profile&#xD;
             of cognitive deficits should be present in at least 2 of the 4 core cognitive domains.&#xD;
             The presence of at least one behavioral symptom supports the diagnosis of probable&#xD;
             PD-D. None of group III and IV features is present. [Possible PD-D] Both core features&#xD;
             must be present. In associated clinical features, the cognitive impairment is atypical&#xD;
             in one or more domains. The behavioral symptoms are not necessary to be present. One&#xD;
             or more of the group III features may be present. No group IV feature is allowed to be&#xD;
             present.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with uncontrollable malignancy, severe heart failure, uremia under&#xD;
             hemodialysis, or decompensated liver cirrhosis.&#xD;
&#xD;
          2. Patients taking anticholinergics within 30 days of recruitment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lane</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, China Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsien-Yuan Lane, M.D., Ph.D</last_name>
    <phone>886 921 067260</phone>
    <email>hylane@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Psychiatry, China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsien-Yuan Lane, M.D., Ph.D</last_name>
      <phone>886 921 067260</phone>
      <email>hylane@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Hsien-Yuan Lane</investigator_full_name>
    <investigator_title>Director, Department of psychiatry, China Medical University Hospital</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>NMDA</keyword>
  <keyword>DAAOI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

